Trial · NCT01092728
Adverse events100
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 100
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Platelet Count Decreased | Blood and lymphatic system disorders | Dasatinib + Completely Resectable | 0 | 4 | 0 |
| other | Platelet Count Decreased | Blood and lymphatic system disorders | Dasatinib + Unresectable | 1 | 14 | 1 |
| other | Vaginal Hemorrhage | Reproductive system and breast disorders | Dasatinib + Completely Resectable | 0 | 4 | 0 |
| other | Vaginal Hemorrhage | Reproductive system and breast disorders | Dasatinib + Unresectable | 1 | 14 | 1 |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Dasatinib + Completely Resectable | 1 | 4 | 1 |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Dasatinib + Unresectable | 3 | 14 | 3 |
| other | Hemoglobin Decreased | Metabolism and nutrition disorders | Dasatinib + Completely Resectable | 0 | 4 | 0 |
| other | Hemoglobin Decreased | Metabolism and nutrition disorders | Dasatinib + Unresectable | 1 | 14 | 1 |
| other | Edema Limbs | Blood and lymphatic system disorders | Dasatinib + Completely Resectable | 0 | 4 | 0 |
| other | Edema Limbs | Blood and lymphatic system disorders | Dasatinib + Unresectable | 7 | 14 | 7 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Dasatinib + Completely Resectable | 2 | 4 | 2 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Dasatinib + Unresectable | 8 | 14 | 11 |
| other | Blood Glucose Increased | Metabolism and nutrition disorders | Dasatinib + Completely Resectable | 0 | 4 | 0 |
| other | Blood Glucose Increased | Metabolism and nutrition disorders | Dasatinib + Unresectable | 1 | 14 | 1 |
| other | Infection | Infections and infestations | Dasatinib + Completely Resectable | 0 | 4 | 0 |
| other | Infection | Infections and infestations | Dasatinib + Unresectable | 5 | 14 | 5 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Dasatinib + Completely Resectable | 1 | 4 | 1 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Dasatinib + Unresectable | 7 | 14 | 8 |
| other | Headache | General disorders | Dasatinib + Completely Resectable | 1 | 4 | 1 |
| other | Headache | General disorders | Dasatinib + Unresectable | 9 | 14 | 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01092728/events